Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of Extracellular Vesicle Isolation Methods for miRNA Sequencing

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Martínez-González, Brenda|||0000-0002-4482-5181
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Núñez-Moreno, Gonzalo|||0000-0001-5982-570X
  • Minguez, Pablo|||0000-0003-4099-9421
  • Burgui, Idoia
  • Ramos-Ruiz, Ricardo|||0000-0002-6331-9786
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Rico, Angie
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Piron, Maria|||0000-0001-6858-9374
  • Corrales Insa, Irene|||0000-0002-0647-0340
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Ramírez Serra, Clara|||0000-0001-8971-1711
  • Camós Anguila, Sílvia|||0000-0002-0478-8494
  • Domingo, Esteban
  • Bes, Marta|||0000-0001-6103-072X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus

  • Martínez-González, Brenda
  • Gallego, Isabel
  • Gregori, Josep
  • Soria, María Eugenia
  • Somovilla, Pilar
  • Ávila, Ana Isabel de
  • García-Crespo, Carlos
  • Durán-Pastor, Antoni
  • Briones, Carlos
  • Gómez, Jordi
  • Quer, Josep
  • Domingo, Esteban
  • Perales, Celia
The concept of a mild mutagen was coined to describe a minor mutagenic activity exhibited by some nucleoside analogues that potentiated their efficacy as antiretroviral agents. In the present study, we report the mild mutagen activity of sofosbuvir (SOF) for hepatitis C virus (HCV). Serial passages of HCV in human hepatoma cells, in the presence of SOF at a concentration well below its cytotoxic concentration 50 (CC) led to pre-extinction populations whose mutant spectra exhibited a significant increase of C!U transitions, relative to populations passaged in the absence of SOF. This was reflected in an increase in several diversity indices that were used to characterize viral quasispecies. The mild mutagenic activity of SOF was largely absent when it was tested with isogenic HCV populations that displayed high replicative fitness. Thus, SOF can act as a mild mutagen for HCV, depending on HCV fitness. Possible mechanisms by which the SOF mutagenic activity may contribute to its antiviral efficacy are discussed., The work at CBMSO was supported by grants SAF2014-52400-R from Ministerio de Economía y Competitividad (MINECO); SAF2017-87846-R and BFU2017-91384-EXP from Ministerio de Ciencia, Innovación y Universidades (MCIU); project 525/C/2021 from Fundació La Marató de TV3; PID2020-113888RB-I00 and 202220I116 from Ministerio de Ciencia e Innovación (MICINN); PI18/00210, PI19/00301, PI21/00139, and PI22/00258 from Instituto de Salud Carlos III (ISCIII); S2013/ABI-2906 (PLATESA from Comunidad de Madrid/FEDER); and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). This research work was also funded by the European Commission-NextGenerationEU (regulation EU 2020/ 2094) through the CSIC’s Global Health Platform (PTI Salud Global). C.P. is supported by the Miguel Servet program of the ISCIII (CP14/00121 and CPII19/00001), cofinanced by the European Regional Development Fund (ERDF). B.M.-G. is supported by the predoctoral contract PFIS FI19/00119 from ISCIII, cofinanced by Fondo Social Europeo (FSE), “El FSE invierte en tu futuro”. C.G.-C. is supported by the predoctoral contract PRE2018-083422 from MCIU. P.S. is supported by the postdoctoral contract Margarita Salas, CA1/RSUE/ 2021 from MCIU. A.D.-P. is supported by the contract 13-2022-008566 cofinanced by the Comunidad de Madrid, through the Programa Investigo, en el marco del Plan de Recuperación, Transformación y Resiliencia, financed by the European Union-Next Generation EU. CIBERehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas), which is funded by ISCIII. The work at CAB was supported by the MICINN grant no. PID2019-104903RB-I00. Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients

  • Llorens Revull, Meritxell
  • Dopazo Taboada, Cristina
  • Rodríguez Frias, Francisco
  • Garcia Cehic, Damir
  • Soria Benito, Maria Eugenia
  • Chen, Qian
  • Perales Viejo, Celia Belen
  • Quer Sivila, Josep
  • Bilbao Aguirre, Itxarone Izaskun
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
Fibrosis; Hepatitis C virus; Viral load, Fibrosis; Virus de la hepatitis C; Carga viral, Fibrosi; Virus de l'hepatitis C; Càrrega viral, Cirrhosis derived from chronic hepatitis C virus (HCV) infection is still a common indication for liver transplantation (LT). Reinfection of the engrafted liver is universal in patients with detectable viral RNA at the time of transplant and causes fast progression of cirrhosis (within 5 years) in around one-third of these patients. To prevent damage to the liver graft, effective direct-acting antiviral (DAA) therapy is required as soon as possible. However, because of post-LT clinical instability, it is difficult to determine the optimal time to start DAAs with a low risk of complications. Evaluate changes in quasispecies complexity following LT and seek a predictive index of fast liver damage progression to determine the timing of DAA initiation. HCV genomes isolated from pre-LT and 15-day post-LT serum samples of ten patients, who underwent orthotopic LT, were quantified and sequenced using a next-generation sequencing platform. Sequence alignments, phylogenetic trees, quasispecies complexity measures, biostatistics analyses, adjusted R2 values, and analysis of variance (ANOVA) were carried out. Three different patterns of reinfection were observed (viral bottlenecking, conserved pre-LT population, and mixed populations), suggesting that bottlenecking or homogenization of the viral population is not a generalized effect after liver graft reinfection. None of the quasispecies complexity measures predicted the future degree of liver damage. Higher and more uniform viral load (VL) values were observed in all pre-LT samples, but values were more dispersed in post-LT samples. However, VL increased significantly from the pre-LT to 15-day post-LT samples in patients with advanced fibrosis at 1-year post-LT, suggesting that a VL increase on day 15 may be a predictor of fast liver fibrosis progression. HCV kinetics after LT differ between patients and are not fibrosis-dependent. Higher VL at day 15 post-LT versus pre-LT samples may predict fast liver fibrosis progression., This study was supported by grants from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF) with grant numbers PI19/00533, PI19/00301, Clinical Trial Gov. Identifier: NCT01707849, and from Centro para el Desarrollo Tecnológico Industrial-CDTI of the Spanish Ministry of Economics and Competitiveness (MINECO) grant number, IDI-20200297. C.P. is supported by the Miguel Servet program of Instituto de Salud Carlos III, grant CP14/00121, cofinanced by the ERDF. Astellas Pharma Inc and Novartis Pharma also provided funding for the study, but these companies had had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens Revull, Meritxell
  • Costafreda Salvany, Maria Isabel
  • Rico Blazquez, Angie
  • Guerrero Murillo, Mercedes
  • Soria Benito, Maria Eugenia
  • Piriz Ruzo, Sofia Romina
  • Vargas Accarino, Elena
  • Gabriel Medina, Pablo
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Esteban Mur, Juan Ignacio
Fibrosi hepàtica; Cèl·lules T; Teràpia de citocines, Fibrosis hepática; Células T; Terapia de citocinas, Liver fibrosis; T cells; Cytokine therapy, Background & aims HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. Methods We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. Results We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Conclusions Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA’s therapies., This study was funded by Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF): grant numbers PI16/00337, PI18/00210 and PI19/00301. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001) cofinanced by the European Regional Development Fund (ERDF).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Chen, Qian
  • Soria, Maria Eugenia
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Nieto, Leonardo|||0000-0002-1336-5645
  • Castells, Lluís|||0000-0002-6672-5931
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Domingo, Esteban
  • Buti, Maria|||0000-0002-0732-3078
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Quer, Josep|||0000-0003-0014-084X
Controversy is ongoing about whether a minority mutant present at frequencies below 15% may be clinically relevant and should be considered to guide treatment. Resistance-associated substitution (RAS) studies were performed in patients before and at failure of antiviral treatments using Next-generation hepatitis C virus (HCV) sequencing (NGS). We have found two patients with genotype 1a infection having RAS in 3.5%-7.1% of the viral population at baseline that were selected during ledipasvir + sofosbuvir treatment. Co-selection of RAS located in a region not directly affected by the antiviral treatment also occurred. This observation calls into question, the recommendations to guide RAS-based direct-acting antiviral (DAA) treatment only when RAS are present in.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus

  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Chen, Qian
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Llorens, Meritxell
  • de Ávila, Ana Isabel
  • Beach, Nathan M.
  • Domingo, Esteban
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Buti, Maria|||0000-0002-0732-3078
  • Esteban, Rafael|||0000-0001-5280-392X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5-10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among treatment-naïve infected individuals. Identification of amino acid substitutions (including those in minority variants) associated with treatment failure requires analytical designs that take into account the high diversification of HCV in more than 86 subtypes according to the ICTV website (June 2017). The methodology has involved five sequential steps: (i) to design 280 oligonucleotide primers (some including a maximum of three degenerate positions), and of which 120 were tested to amplify NS3, NS5A-, and NS5B-coding regions in a subtype-specific manner, (ii) to define a reference sequence for each subtype, (iii) to perform experimental controls to define a cut-off value for detection of minority amino acids, (iv) to establish bioinformatics' tools to quantify amino acid replacements, and (v) to validate the procedure with patient samples. A robust ultra-deep sequencing procedure to analyze HCV circulating in serum samples from patients infected with virus that belongs to the ten most prevalent subtypes worldwide: 1a, 1b, 2a, 2b, 2c, 2j, 3a, 4d, 4e, 4f has been developed. Oligonucleotide primers are subtype-specific. A cut-off value of 1% mutant frequency has been established for individual mutations and haplotypes. The methodological pipeline described here is adequate to characterize in-depth mutant spectra of HCV populations, and it provides a tool to understand HCV diversification and treatment failures. The pipeline can be periodically extended in the event of HCV diversification into new genotypes or subtypes, and provides a framework applicable to other RNA viral pathogens, with potential to couple detection of drug-resistant mutations with treatment planning. The online version of this article (10.1186/s12879-018-3356-6) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rare haplotype load as marker for lethal mutagenesis

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gallego, Isabel
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Domingo, Esteban
RNA viruses replicate with a template-copying fidelity, which lies close to an extinction threshold. Increases of mutation rate by nucleotide analogues can drive viruses towards extinction. This transition is the basis of an antiviral strategy termed lethal mutagenesis. We have introduced a new diversity index, the rare haplotype load (RHL), to describe NS5B (polymerase) mutant spectra of hepatitis C virus (HCV) populations passaged in absence or presence of the mutagenic agents favipiravir or ribavirin. The increase in RHL is more prominent in mutant spectra whose expansions were due to nucleotide analogues than to multiple passages in absence of mutagens. Statistical tests for paired mutagenized versus non-mutagenized samples with 14 diversity indices show that RHL provides consistently the highest standardized effect of mutagenic treatment difference for ribavirin and favipiravir. The results indicate that the enrichment of viral quasispecies in very low frequency minority genomes can serve as a robust marker for lethal mutagenesis. The diagnostic value of RHL from deep sequencing data is relevant to experimental studies on enhanced mutagenesis of viruses, and to pharmacological evaluations of inhibitors suspected to have a mutagenic activity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir

  • de Ávila, Ana Isabel
  • Gallego, Isabel
  • Soria, Maria Eugenia
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Rice, Charles M.|||0000-0003-3087-8079
  • Domingo, Esteban
  • Perales Viejo, Celia|||0000-0003-1618-1937
Lethal mutagenesis is an antiviral approach that consists in extinguishing a virus by an excess of mutations acquired during replication in the presence of a mutagen. Here we show that favipiravir (T-705) is a potent mutagenic agent for hepatitis C virus (HCV) during its replication in human hepatoma cells. T-705 leads to an excess of G → A and C → U transitions in the mutant spectrum of preextinction HCV populations. Infectivity decreased significantly in the presence of concentrations of T-705 which are 2- to 8-fold lower than its cytotoxic concentration 50 (CC). Passaging the virus five times in the presence of 400 μM T-705 resulted in virus extinction. Since T-705 has undergone advanced clinical trials for approval for human use, the results open a new approach based on lethal mutagenesis to treat hepatitis C virus infections. If proven effective for HCV in vivo, this new anti-HCV agent may be useful in patient groups that fail current therapeutic regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies

  • Martín, Verónica|||0000-0003-1486-1656
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Fernández-Algar, María
  • Dos Santos, Helena G.
  • Garrido, Patricia
  • Pernas, María
  • Parro, Víctor
  • Moreno, Miguel
  • García-Pérez, Javier|||0000-0003-0300-1810
  • Alcami, Jose|||0000-0003-0023-7377
  • Torán, José Luis
  • Abia, David|||0000-0003-0401-7590
  • Domingo, Esteban
  • Briones Llorente, Carlos|||0000-0003-2213-8353
The response of human immunodeficiency virus type 1 (HIV-1) quasispecies to antiretroviral therapy is influenced by the ensemble of mutants that composes the evolving population. Low-abundance subpopulations within HIV-1 quasispecies may determine the viral response to the administered drug combinations. However, routine sequencing assays available to clinical laboratories do not recognize HIV-1 minority variants representing less than 25% of the population. Although several alternative and more sensitive genotyping techniques have been developed, including next-generation sequencing (NGS) methods, they are usually very time consuming, expensive and require highly trained personnel, thus becoming unrealistic approaches in daily clinical practice. Here we describe the development and testing of a HIV-1 genotyping DNA microarray that detects and quantifies, in majority and minority viral subpopulations, relevant mutations and amino acid insertions in 42 codons of the pol gene associated with drug- and multidrug-resistance to protease (PR) and reverse transcriptase (RT) inhibitors. A customized bioinformatics protocol has been implemented to analyze the microarray hybridization data by including a new normalization procedure and a stepwise filtering algorithm, which resulted in the highly accurate (96.33%) detection of positive/negative signals. This microarray has been tested with 57 subtype B HIV-1 clinical samples extracted from multi-treated patients, showing an overall identification of 95.53% and 89.24% of the queried PR and RT codons, respectively, and enough sensitivity to detect minority subpopulations representing as low as 5-10% of the total quasispecies. The developed genotyping platform represents an efficient diagnostic and prognostic tool useful to personalize antiviral treatments in clinical practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
  • Rico, Angie
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Soria, Maria Eugenia
  • Píriz-Ruzo, Sofía
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Gabriel-Medina, Pablo|||0000-0003-3079-6364
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Quer, Josep|||0000-0003-0014-084X
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Bes, Marta|||0000-0001-6103-072X
HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA's therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Dopazo, Cristina|||0000-0001-6274-5911
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Chen, Qian
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Bilbao, Itxarone|||0000-0002-7389-395X
Cirrhosis derived from chronic hepatitis C virus (HCV) infection is still a common indication for liver transplantation (LT). Reinfection of the engrafted liver is universal in patients with detectable viral RNA at the time of transplant and causes fast progression of cirrhosis (within 5 years) in around one-third of these patients. To prevent damage to the liver graft, effective direct-acting antiviral (DAA) therapy is required as soon as possible. However, because of post-LT clinical instability, it is difficult to determine the optimal time to start DAAs with a low risk of complications. Evaluate changes in quasispecies complexity following LT and seek a predictive index of fast liver damage progression to determine the timing of DAA initiation. HCV genomes isolated from pre-LT and 15-day post-LT serum samples of ten patients, who underwent orthotopic LT, were quantified and sequenced using a next-generation sequencing platform. Sequence alignments, phylogenetic trees, quasispecies complexity measures, biostatistics analyses, adjusted R2 values, and analysis of variance (ANOVA) were carried out. Three different patterns of reinfection were observed (viral bottlenecking, conserved pre-LT population, and mixed populations), suggesting that bottlenecking or homogenization of the viral population is not a generalized effect after liver graft reinfection. None of the quasispecies complexity measures predicted the future degree of liver damage. Higher and more uniform viral load (VL) values were observed in all pre-LT samples, but values were more dispersed in post-LT samples. However, VL increased significantly from the pre-LT to 15-day post-LT samples in patients with advanced fibrosis at 1-year post-LT, suggesting that a VL increase on day 15 may be a predictor of fast liver fibrosis progression. HCV kinetics after LT differ between patients and are not fibrosis-dependent. Higher VL at day 15 post-LT versus pre-LT samples may predict fast liver fibrosis progression.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients

  • Llorens Revull, Meritxell
  • Dopazo Taboada, Cristina
  • Rodríguez Frias, Francisco
  • Garcia Cehic, Damir
  • Soria Benito, Maria Eugenia
  • Chen, Qian
  • Perales Viejo, Celia Belen
  • Quer Sivila, Josep
  • Bilbao Aguirre, Itxarone Izaskun
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
Fibrosis; Hepatitis C virus; Viral load, Fibrosis; Virus de la hepatitis C; Carga viral, Fibrosi; Virus de l'hepatitis C; Càrrega viral, Cirrhosis derived from chronic hepatitis C virus (HCV) infection is still a common indication for liver transplantation (LT). Reinfection of the engrafted liver is universal in patients with detectable viral RNA at the time of transplant and causes fast progression of cirrhosis (within 5 years) in around one-third of these patients. To prevent damage to the liver graft, effective direct-acting antiviral (DAA) therapy is required as soon as possible. However, because of post-LT clinical instability, it is difficult to determine the optimal time to start DAAs with a low risk of complications. Evaluate changes in quasispecies complexity following LT and seek a predictive index of fast liver damage progression to determine the timing of DAA initiation. HCV genomes isolated from pre-LT and 15-day post-LT serum samples of ten patients, who underwent orthotopic LT, were quantified and sequenced using a next-generation sequencing platform. Sequence alignments, phylogenetic trees, quasispecies complexity measures, biostatistics analyses, adjusted R2 values, and analysis of variance (ANOVA) were carried out. Three different patterns of reinfection were observed (viral bottlenecking, conserved pre-LT population, and mixed populations), suggesting that bottlenecking or homogenization of the viral population is not a generalized effect after liver graft reinfection. None of the quasispecies complexity measures predicted the future degree of liver damage. Higher and more uniform viral load (VL) values were observed in all pre-LT samples, but values were more dispersed in post-LT samples. However, VL increased significantly from the pre-LT to 15-day post-LT samples in patients with advanced fibrosis at 1-year post-LT, suggesting that a VL increase on day 15 may be a predictor of fast liver fibrosis progression. HCV kinetics after LT differ between patients and are not fibrosis-dependent. Higher VL at day 15 post-LT versus pre-LT samples may predict fast liver fibrosis progression., This study was supported by grants from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF) with grant numbers PI19/00533, PI19/00301, Clinical Trial Gov. Identifier: NCT01707849, and from Centro para el Desarrollo Tecnológico Industrial-CDTI of the Spanish Ministry of Economics and Competitiveness (MINECO) grant number, IDI-20200297. C.P. is supported by the Miguel Servet program of Instituto de Salud Carlos III, grant CP14/00121, cofinanced by the ERDF. Astellas Pharma Inc and Novartis Pharma also provided funding for the study, but these companies had had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens Revull, Meritxell
  • Costafreda Salvany, Maria Isabel
  • Rico Blazquez, Angie
  • Guerrero Murillo, Mercedes
  • Soria Benito, Maria Eugenia
  • Piriz Ruzo, Sofia Romina
  • Vargas Accarino, Elena
  • Gabriel Medina, Pablo
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Esteban Mur, Juan Ignacio
Fibrosi hepàtica; Cèl·lules T; Teràpia de citocines, Fibrosis hepática; Células T; Terapia de citocinas, Liver fibrosis; T cells; Cytokine therapy, Background & aims HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. Methods We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. Results We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Conclusions Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA’s therapies., This study was funded by Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF): grant numbers PI16/00337, PI18/00210 and PI19/00301. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001) cofinanced by the European Regional Development Fund (ERDF).